Cargando…
Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells
Histone deacetylase inhibitors (HDIs) are a group of potent epigenetic drugs which have been investigated for their therapeutic potential in various clinical disorders, including hematological malignancies and solid tumors. Currently, several HDIs are already in clinical use and many more are on cli...
Autores principales: | Wawruszak, Anna, Kalafut, Joanna, Okon, Estera, Czapinski, Jakub, Halasa, Marta, Przybyszewska, Alicja, Miziak, Paulina, Okla, Karolina, Rivero-Muller, Adolfo, Stepulak, Andrzej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406474/ https://www.ncbi.nlm.nih.gov/pubmed/30691229 http://dx.doi.org/10.3390/cancers11020148 |
Ejemplares similares
-
Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties
por: Wawruszak, Anna, et al.
Publicado: (2019) -
Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity—An Isobolographic Analysis
por: Wawruszak, Anna, et al.
Publicado: (2019) -
Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together
por: Wawruszak, Anna, et al.
Publicado: (2021) -
Antagonistic Interaction between Histone Deacetylase Inhibitor: Cambinol and Cisplatin—An Isobolographic Analysis in Breast Cancer In Vitro Models
por: Hałasa, Marta, et al.
Publicado: (2021) -
Synthetic circuits based on split Cas9 to detect cellular events
por: Przybyszewska-Podstawka, Alicja, et al.
Publicado: (2023)